IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/24/2023 | $38.00 | Equal Weight | Wells Fargo |
| 5/22/2023 | $71.00 | Buy | Canaccord Genuity |
| 3/31/2023 | $56.00 | Buy | Needham |
| 3/1/2023 | Outperform | TD Cowen | |
| 3/1/2023 | Outperform | Cowen | |
| 11/15/2022 | $65.00 | Buy | Guggenheim |
| 9/14/2022 | $36.00 | Overweight | Cantor Fitzgerald |
| 9/7/2022 | $37.00 | Buy | Stifel |
| 7/18/2022 | $40.00 | Buy | H.C. Wainwright |
| 10/11/2021 | $46.00 | Outperform | SVB Leerink |
15-12G - DICE Therapeutics, Inc. (0001645569) (Filer)
EFFECT - DICE Therapeutics, Inc. (0001645569) (Filer)
S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)
S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)
S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)
POSASR - DICE Therapeutics, Inc. (0001645569) (Filer)
POS AM - DICE Therapeutics, Inc. (0001645569) (Filer)
8-K - DICE Therapeutics, Inc. (0001645569) (Filer)
SC 14D9/A - DICE Therapeutics, Inc. (0001645569) (Subject)
SC TO-T/A - DICE Therapeutics, Inc. (0001645569) (Subject)